{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:18:37Z","timestamp":1790605117599,"version":"4.1.0"},"reference-count":30,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: This study compared chest high-resolution computed tomography (HRCT) findings between patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive and antibody-negative progressive pulmonary fibrosis (PPF) with polymyositis\/dermatomyositis (PM\/DM). Methods: Of the 85 patients with PM\/DM-interstitial lung disease (ILD), 17 were anti-MDA5 antibody-positive, and 68 were antibody-negative. Among these, 5 anti-MDA5 antibody-positive and 9 antibody-negative cases met the criteria for PPF and were enrolled in the study. The chest HRCT findings and the duration from treatment initiation to the appearance of key fibrotic changes were analyzed. Results: In the anti-MDA5-positive group, all patients were diagnosed with PPF within 6 months of treatment initiation, compared to only 22.2% in the anti-MDA5-negative group. While there was no difference between the anti-MDA5 antibody-positive and antibody-negative groups in terms of chest HRCT findings associated with PPF, the duration to the appearance of increased traction bronchiectasis and bronchiolectasis, and new ground-glass opacity with traction bronchiectasis was significantly shorter in the anti-MDA5-positive group (p = 0.016 and p = 0.023, respectively). The appearance of new fine reticulations and increased coarseness of reticular abnormalities tended to be shorter in the anti-MDA5 antibody-positive group than in the antibody-negative group. Conclusions: Pulmonary fibrosis in patients with anti-MDA5 antibody-positive ILD can rapidly progress within 6 months, despite immunosuppressive therapy. Frequent HRCT monitoring and early combination therapy with antifibrotic agents are crucial for managing the progression of fibrosis.<\/jats:p>","DOI":"10.3390\/jcm14051601","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T03:37:57Z","timestamp":1740627477000},"page":"1601","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of Chest High-Resolution Computed Tomography Findings in Patients with Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive and Antibody-Negative Progressive Pulmonary Fibrosis with Polymyositis\/Dermatomyositis"],"prefix":"10.3390","volume":"14","author":[{"given":"Noboro","family":"Sato","sequence":"first","affiliation":[{"name":"Department of Diagnostic Radiology, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Osaka, Japan"},{"name":"Department of Radiology, Tominaga Hospital, Osaka 556-0017, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Kotani","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (IV), Division of Rheumatology, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Koyama","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Osaka, Japan"},{"name":"Department of Radiology, Ikeda City Hospital, Ikeda 563-8510, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (IV), Division of Rheumatology, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (IV), Division of Rheumatology, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Shou","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (IV), Division of Rheumatology, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumasa","family":"Oe","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (IV), Division of Rheumatology, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0065-929X","authenticated-orcid":false,"given":"Tohru","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (IV), Division of Rheumatology, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Osuga","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00408-016-9896-x","article-title":"Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease","volume":"194","author":"Johnson","year":"2016","journal-title":"Lung"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Zhang, L., Wu, G., Gao, D., Liu, G., Pan, L., Ni, L., Li, Z., and Wang, Q. (2016). Factors associated with interstitial lung disease in patients with polymyositis and dermatomyositis: A systematic review and meta-analysis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0155381"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nrrheum.2016.120","article-title":"Inflammatory myopathies: Choosing the right biomarkers to predict ILD in myositis","volume":"12","author":"Gono","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/08916930600622884","article-title":"Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies","volume":"39","author":"Yoshifuji","year":"2006","journal-title":"Autoimmunity"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00296-017-3729-y","article-title":"Comparison of long-term prognosis and relapse of dermatomyositis complicated with interstitial pneumonia according to autoantibodies: Anti-aminoacyl tRNA synthetase antibodies versus anti-melanoma differentiation-associated gene 5 antibody","volume":"37","author":"Isoda","year":"2017","journal-title":"Rheumatol. Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/rheumatology\/key060","article-title":"Initial predictors of poor survival in myositis-associated interstitial lung disease: A multicentre cohort of 497 patients","volume":"57","author":"Sato","year":"2018","journal-title":"Rheumatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e000212","DOI":"10.1136\/bmjresp-2017-000212","article-title":"Design of the PF-ILD trial: A double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease","volume":"4","author":"Flaherty","year":"2017","journal-title":"BMJ Open Respir. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"230090","DOI":"10.1183\/20734735.0090-2023","article-title":"Add-on therapy for pulmonary fibrosis, a forthcoming era with implications for practice: The BI 101550 and RELIEF trials","volume":"19","author":"Fabbri","year":"2023","journal-title":"Breathe"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e003121","DOI":"10.1136\/rmdopen-2023-003121","article-title":"Interstitial lung disease with and without progressive fibrosing phenotype in patients with idiopathic inflammatory myopathies: Data from a large multicentric cohort","volume":"9","author":"Zanatta","year":"2023","journal-title":"RMD Open"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Wang, H., Wang, Y., Sun, D., Yu, S., Du, X., and Ye, Q. (2024). Progressive pulmonary fibrosis in myositis-specific antibody-positive interstitial pneumonia: A retrospective cohort study. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1325082"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0733-8635(02)00021-9","article-title":"Dermatomyositis: An overview of recent progress with emphasis on dermatologic aspects","volume":"20","author":"Sontheimer","year":"2002","journal-title":"Dermatol. Clin."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jaad.2005.10.041","article-title":"A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sin\u00e9 myositis): A missing link within the spectrum of the idiopathic inflammatory myopathies","volume":"54","author":"Gerami","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.autrev.2012.06.006","article-title":"Hierarchical cluster and survival analyses of antisynthetase syndrome: Phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity","volume":"12","author":"Hervier","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"American Thoracic Society, and European Respiratory Society (2002). American Thoracic Society\/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am. J. Respir. Crit. Care Med., 165, 277\u2013304.","DOI":"10.1164\/ajrccm.165.2.ats01"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1378\/chest.93.3.580","article-title":"Evaluation of clinical methods for rating dyspnea","volume":"93","author":"Mahler","year":"1988","journal-title":"Chest"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Isoda, K., Takeuchi, T., Kotani, T., Hata, K., Shoda, T., Ishida, T., Yoshida, S., Kimura, Y., Makino, S., and Hanafusa, T. (2014). Pre-treatment ferritin level and alveolar-arterial oxygen gradient can predict mortality rate due to acute\/subacute interstitial pneumonia in dermatomyositis treated by cyclosporine a\/glucocorticosteroid combination therapy: A case control study. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0089610"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/art.24621","article-title":"RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease","volume":"60","author":"Sato","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e003150","DOI":"10.1136\/rmdopen-2023-003150","article-title":"Clinical, radiological and pathological features of anti-MDA5 antibody-associated interstitial lung disease","volume":"9","author":"Chen","year":"2023","journal-title":"RMD Open"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Fujisawa, T., Hozumi, H., Kono, M., Enomoto, N., Hashimoto, D., Nakamura, Y., Inui, N., Yokomura, K., Koshimizu, N., and Toyoshima, M. (2014). Prognostic factors for myositis-associated interstitial lung disease. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0098824"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3109\/14397595.2015.1134392","article-title":"Initial limited three-level thin-section computed tomography scorings predict the prognosis of acute\/subacute interstitial pneumonia in patients with dermatomyositis","volume":"26","author":"Kotani","year":"2016","journal-title":"Mod. Rheumatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"833.e1","DOI":"10.1016\/j.crad.2018.04.017","article-title":"HRCT findings of collagen vascular disease-related interstitial pneumonia (CVD-IP): A comparative study among individual underlying diseases","volume":"73","author":"Tanaka","year":"2018","journal-title":"Clin. Radiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.rmed.2011.05.006","article-title":"HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody","volume":"105","author":"Tanizawa","year":"2011","journal-title":"Respir. Med."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Egashira, R. (2021). High-resolution CT findings of myositis-related interstitial lung disease. Medicina, 57.","DOI":"10.3390\/medicina57070692"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4775","DOI":"10.2147\/IJGM.S327751","article-title":"Evaluation of prognostic factors in anti-MDA5 antibody-positive patients in Chongqing, China: A retrospective study","volume":"14","author":"Zhou","year":"2021","journal-title":"Int. J. Gen. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.ejrad.2016.05.012","article-title":"Antisynthetase syndrome: Pulmonary computed tomography findings of adult patients with antibodies to aminoacyl-tRNA synthetases","volume":"85","author":"Waseda","year":"2016","journal-title":"Eur. J. Radiol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/5\/1601\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:43:02Z","timestamp":1760028182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/5\/1601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["jcm14051601"],"URL":"https:\/\/doi.org\/10.3390\/jcm14051601","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]}}}